Research of Warfarin Anticoagulation Therapy in Atrial Fibrillation Patients with Non-Valvular Heart Disease

Objective To investigate the antithrombotic effect and the bleeding risk of Warfarin anticoagulation therapy in patients with non-valvular atrial fibrillation (AF). Methods 74 cases of treatment group were taken with Warfarin from 1.5 mg one time/d, adjusting dose according to prothrombin time international normalized ratio (INR). INR standard in the treatment group reached 2.0 ~ 3.0. The patients continued taking Warfarin and were followed up for one year. 66 cases of the control group continued taking placebo and were followed up for one year. Embolic events and bleeding rates of the two groups were observed. Results The embolism rate was 0% and the bleeding rate was 2.7% in the treatment group, 4.5% and 0%% in the control group, with statistically significant difference (P 0.01). Conclusions For patients with non-valvular AF treated with Warfarin anticoagulation, Warfarin target INR is safe and effective between 2.0 and 3.0.